Clinical Trial

Rwanda Digital Dashboard Hybrid Type 3 Implementation Study

Recruiting
View on ClinicalTrials.gov →
Summary
Mental disorders are leading causes of the health-related burden globally, and in Rwanda the intergenerational mental health consequences of the 1994 Genocide against the Tutsi persist and are further compounded by poverty, such that recent studies have found 20% of the Rwandan population has one or more mental disorders. The Research Program on Children and Adversity (RPCA) has expanded its evidence-based home-visiting Sugira Muryango (SM) in Rwanda. The current study aims to assess a digitally enhanced delivery of Sugira Muryango to meet the needs of the Government of Rwanda in expanding the mental health and social services infrastructure. The proposed research will test the feasibility, acceptability and impact of a technology-enabled service delivery model using a digital tool that streamlines data collection, improves visibility of key program performance metrics, and serves as a resource for learning materials that can be used for continuous learning and training of a non-specialized workforce that is delivering an evidence-based intervention that improves caregiver mental health and family functioning. What the team learn from technology-supported delivery of Sugira Muryango - an evidence-based, trauma-informed, family-based behavioral intervention in Rwanda - can be used to improve the efficiency, effectiveness, and scalability of evidence-based mental health services in Rwanda and globally.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-04-17; most recent amendment 2026-03-24.
Trial Details
NCT Number NCT06941831
Lead Sponsor Boston College
Collaborators: National Institute of Mental Health (NIMH)
Conditions IPV, Mental Health, Discipline Practices, Quality Assurance, Provider Confidence, Provider Skill, Quality of Life
Enrollment 1,810 participants
Start Date 2025-01-30
Primary Completion 2027-06-30 (estimated)
Study Completion 2029-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-27